Karuna Therapeutics Inc., of Boston, submitted a draft registration statement on Form S-1 with the SEC relating to the proposed IPO of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is expected to commence after the SEC completes its review process, subject to market and other conditions.